Radius osteoporosis study misses endpoint

 

• The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®

• Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%

• Both abalo-TDS and TYMLOS 12-month results are considered clinically meaningful

• Abalo-TDS was well tolerated with no significant safety signals identified

• Trial data and technical details to be fully analyzed and then utilized as a basis for future plans

https://finance.yahoo.com/news/radius-announces-results-wearable-trial-140000324.html